Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1295 • ACR Convergence 2020
Disease Activity and Mental Health in SLE Patients: A Cross-section Study with Self-Assessments Based on Smart System of Disease Management (SSDM) Mobile Tools
Yongfu Wang¹, Hua Wei², Rui Wu³, Jianhong Wu⁴, Shengtao Zhang⁵, Qin Li⁶, Yang Li⁷, You Sun⁷, Yanping Zhao⁸, Qiang Shu⁹, Lirong Kang¹, Bin Wu¹⁰, Li Qin¹¹, Feng Jiang¹¹, Huiqin Yang¹², Junli Zhang¹³, Hui Xiao¹⁴, Bing Wu¹⁵, Yuhua Jia¹⁵, Fei Xiao¹⁵ and Lingyun Sun¹⁶, ¹The First Affiliated Hospital of BaoTou Medical College, Inner Mongolia University of Science and Technology, Baotou, China (People's Republic), ²Northern Jiangsu People's Hospital, Yangzhou, China (People's Republic), ³The First Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ⁴Department of Rheumatology, Dazhou Central Hospital, Dazhou, China (People's Republic), ⁵Tongji Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China (People's Republic), ⁶The First People's Hospital of Yunnan Province, Kunming, China (People's Republic), ⁷The Second Affiliated Hospital of Harbin Medical University, Harbin, China (People's Republic), ⁸First Affiliated Hospital of Harbin Medical University, Harbin, China (People's Republic), ⁹Qilu Hospital of Shandong University, Jinan, China (People's Republic), ¹⁰The First People's Hospital of Jingzhou, Jingzhou, China (People's Republic), ¹¹The No.3 People’s Hospital of HuZhou City, Huzhou, China (People's Republic), ¹²Wuhan No. 1 Hospital, Wuhan, China (People's Republic), ¹³Xi'an No. 5 Hospital, Xi'an, China (People's Republic), ¹⁴Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹⁵Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁶Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China (People's Republic)
Background/Purpose: WHO survey showed that the prevalence of anxiety and depression in Chinese population and Chinese patients with chronic diseases were between 3.1% - 4.2%…
Abstract Number: 1499 • ACR Convergence 2020
The Frequency of Contraception Documentation in Women with Lupus and Rheumatoid Arthritis Within the RISE Registry
Megan Clowse¹, Jing Li², Amanda Eudy³, Mehret Birru Talabi⁴ and Gabriela Schmajuk⁵, ¹Duke University, Chapel Hill, NC, ²University of California, San Francisco, San Francisco, CA, ³Duke University, Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of California, San Francisco, Atherton, CA
Background/Purpose: Several of the most commonly prescribed anti-rheumatic medications for women with rheumatic disease are known teratogens, posing a risk for pregnancy loss and birth…
Abstract Number: 1621 • ACR Convergence 2020
Cervical Cancer Screening Among Women with Systemic Lupus Erythematosus or Prescribed Tumor Necrosis Alpha-inhibitors Who Receive Outpatient Rheumatology Care
Mehret Birru Talabi¹, Kwonho Jeong¹, Kaleab Abebe¹, Megan Clowse², Robyn Domsic³ and Sonya Borrero¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Duke University, Chapel Hill, NC, ³University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Cervical cancer screening is important for women with systemic lupus erythematosus (SLE) and women prescribed TNF-alpha inhibitors (TNFi), as they have an increased risk…
Abstract Number: 1681 • ACR Convergence 2020
Hemophagocytic Lymphohistiocytosis (HLH) Gene Variants in Childhood-onset SLE (cSLE) with Macrophage Activation Syndrome (MAS)
Piya Lahiry¹, Sergey Naumenko², Fangming Liao³, Daniela Dominguez⁴, Andrea Knight⁵, Deborah Levy⁶, Melissa Misztal⁷, Lawrence Ng⁸, Earl D. Silverman⁹ and Linda Hiraki¹⁰, ¹Hospital for Sick Children, Toronto, ON, Canada, ²The Centre for Computational Medicine, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada, ³Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁷Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Oakville, ON, Canada, ⁸Division of Rheumatology, Hospital for Sick Children, Toronto, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ¹⁰Division of Rheumatology, The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada
Background/Purpose: Familial Hemophagocytic lymphohistiocytosis (fHLH) is an autosomal recessive, hyper-inflammatory, life-threatening disease. Macrophage activation syndrome (MAS) is also known as secondary HLH due to the…
Abstract Number: 1793 • ACR Convergence 2020
Safety of Obtaining Research Tissue During Clinically Indicated Kidney Biopsies: Data from the Lupus Accelerating Medicines Partnership
Kristina Deonaraine¹, Philip Carlucci¹, Andrea Fava², Jessica Li³, David Wofsy⁴, Judith James⁵, Chaim Putterman⁶, Betty Diamond⁷, Derek Fine⁸, Jose Monroy-Trujillo⁸, Kristin Haag⁸, William Apruzzese⁹, H. Michael Belmont¹⁰, Peter Izmirly¹¹, Sean Connery¹², Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Partnership in SLE Network¹⁹, Michelle Petri²⁰ and Jill Buyon²¹, ¹New York University School of Medicine, New York, ²Johns Hopkins, Baltimore, ³Johns Hopkins University, Baltimore, MD, ⁴University of California San Francisco, San Francisco, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Northwell Health, Hartford, ⁸Johns Hopkins University, Baltimore, ⁹., Boston, ¹⁰NYU School of Medicine, New York, NY, ¹¹Department of Medicine, New York University School of Medicine, New York, NY, ¹²Texas Tech University Health Sciences Center, Lubbock, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶University of California San Francisco, San Francisco, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸School of Health Sciences, University of California, La Jolla, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, ²¹New York University, New York, NY
Background/Purpose: Lupus nephritis (LN) is a major complication of systemic lupus erythematous (SLE) and affects ~60% of patients during the course of their disease, leading…
Abstract Number: 1810 • ACR Convergence 2020
Complement Activation in Systemic Lupus Erythematosus Patients with Low Disease Activity Is Not Inhibited by Hydroxychloroquine
Anne Margrethe Troldborg¹, Annette Hansen², Kristian Stengaard-Pedersen² and Steffen Thiel², ¹Aarhus University Hospital, Arhus, Denmark, ²Aarhus University, Aarhus, Denmark
Background/Purpose: Mortality in patients with systemic lupus erythematosus (SLE) is significantly higher than in the general population. Treatment of SLE patients has improved, however, a…
Abstract Number: 1827 • ACR Convergence 2020
Flare Reduction and Oral Corticosteroid Taper in Patients with Active SLE Treated with Anifrolumab in 2 Phase 3 Trials
Richard Furie¹, Eric Morand², Anca Askanase³, Ed Vital⁴, Joan Merrill⁵, Rubana Kalyani⁶, Gabriel Abreu⁷, Lilia Pineda⁶ and Raj Tummala⁶, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, ²Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ³Columbia University College of Physicians and Surgeons, New York, ⁴University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Objectives of long-term SLE management are not only to reduce disease activity, but also to prevent flares and minimize exposure to oral corticosteroids (OCS),…
Abstract Number: 1845 • ACR Convergence 2020
Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol: A Matched Case-Control Study
Dario Roccatello¹, Savino Sciascia², Roberta Fenoglio² and Rossi Daniela², ¹S Giovanni Hospital, Univ of Turin, Turin, Italy, ²University of Torino, Torino, Italy
Background/Purpose: Targeting B-cells remains an attractive option in Lupus Nephritis (LN) despite the negative results of RCTs.Methods: Sixty patients with active LN were included in…
Abstract Number: 170 • 2020 Pediatric Rheumatology Symposium
Clinical Team Perspectives on the Transition from Pediatric to Adult Care for Patients with Childhood-Onset SLE
Nicole Bitencourt¹, Justin Kramer ², Bonnie Bermas ³, Elizabeth Solow ², Tracey Wright ² and Una Makris ², ¹UT Southwestern Medical Center, Dallas, Texas, ²UT Southwestern Medical Center, Dallas, ³UTSouthwestern Medical Center, Dallas
Background/Purpose: The transition from pediatric to adult care for youth with chronic disease is known to be a vulnerable period, with adverse outcomes described for…
Abstract Number: 176 • 2020 Pediatric Rheumatology Symposium
Implementation of an Abbreviated Neuropsychology Screening Protocol for Patients Diagnosed with Childhood-onset Systemic Lupus Erythematosus
Camille Wilson¹, Alana Leever ¹, Jennifer Cass ¹, Vidya Sivaraman ² and Stacy Ardoin ¹, ¹Nationwide Children's Hospital, Columbus, ²Division of Rheumatology, Nationwide Children's Hospital, Bexley
Background/Purpose: Research has established that a large percentage of individuals diagnosed with childhood-onset systemic lupus erythematosus (cSLE) report cognitive dysfunction. Disease factors that can impact…
Abstract Number: 177 • 2020 Pediatric Rheumatology Symposium
Educational Outcomes in a Young-Adult Cohort of Patients with Childhood Onset Systemic Lupus Erythematosus (SLE)
Anita Dhanrajani¹, Earl D. Silverman ², Andrea Knight ³, Deborah Levy ⁴ and Amanda Steiman ⁵, ¹Hospital for Sick Kids, Edmonton, Alberta, Canada, ²Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, ³SickKids Research Institute, Toronto, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, Canada, ⁵Sinai Health System, Toronto, Ontario, Canada
Background/Purpose: The literature regarding educational and socioeconomic outcomes in young adults with childhood-onset Systemic Lupus Erythematosus (cSLE) are sparse. cSLE patients recently transitioned to adult…
Abstract Number: 186 • 2020 Pediatric Rheumatology Symposium
Anthropometric Assessment and Food Intake of Parents of Pediatric Patients with Chronic Rheumatic Diseases
Lucila Pereira¹, Agatha Nogueira Previdelli ², Rosana Gomes de Torres Rossi ², Wellington Douglas Rodrigues ³, Fernado Luiz Affonso Fonseca ³, Claudio Len ⁴, Roseli Oselka Saccardo Sarni ³ and Maria Teresa Terreri ⁴, ¹Federal University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²Sao Judas Tadeu University, Sao Paulo, Brazil, ³Federal University of Sao Paulo, Sao Paulo, Brazil, ⁴Sao Paulo, Brazil
Background/Purpose: Chronic rheumatic diseases in children and adolescents increase cardiovascular risk. Thus, knowing the eating habits, biomarkers of lipid metabolism and the lifestyle of patients…
Abstract Number: 032 • 2020 Pediatric Rheumatology Symposium
The Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth with Systemic Lupus Erythematosus
Joyce Chang¹, Alaina Davis ², Marisa Klein-Gitelman ³, Zuleyha Cidav ⁴, David Mandell ⁵ and Andrea Knight ⁶, ¹Children's Hospital of Philadelphia, Philadelphia, ²Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee, ³Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁶SickKids Research Institute, Toronto, Canada
Background/Purpose: Youth with systemic lupus erythematosus (SLE) experience significant health care burden and high rates of psychiatric disorders. Optimizing medication adherence is critical for preventing…
Abstract Number: 033 • 2020 Pediatric Rheumatology Symposium
Parental Adverse Childhood Experience (ACE) Exposure Is Predictive of Active Lupus in Pediatric Patients
Michael Nelson¹, Nancy Correa ², Ashley Butler ¹, Marietta De Guzman ³, Bethanie Van Horne ¹ and Christopher Greeley ¹, ¹Baylor College of Medicine, Houston, ²Texas Children's Hospital, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Adverse Childhood Experiences (ACEs) have been recognized for more than two decades as risk factors for poor health outcomes in adults. Nevertheless, the impact…
Abstract Number: 035 • 2020 Pediatric Rheumatology Symposium
The Childhood and Rheumatology Research Alliance Systemic Lupus Erythematosus and Related Disorders Cohort
Stacy Ardoin¹, Stephen Balevic ², Aimee Hersh ³, Yukiko Kimura ⁴, Andrea Knight ⁵, Laura Schanberg ⁶, Mary Beth Son ⁷ and Timothy Beukelman ⁸ for the CARRA investigators, ¹Nationwide Children's Hospital, Columbus, ²Duke University, Hillsborough, ³University of Utah Primary Children's Hospital, Salt Lake City, ⁴Hackensack Meridian School of Medicine, Hackensack, ⁵SickKids Research Institute, Toronto, Canada, ⁶Duke Children's Hospital & Health Center, Durham, North Carolina, ⁷Boston Children's Hospital, Boston, Massachusetts, ⁸University of Alabama at Birmingham, Birmingham
Background/Purpose: Optimal therapy in childhood onset systemic lupus erythematosus (SLE) lack sufficient data to support clinical decision making. To address this knowledge gap, the Childhood…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.